Skip to main content

Advertisement

SpringerLink
Log in

Calcium pyrophosphate dihydrate and hydroxyapatite crystal deposition in the joint: New developments relevant to the clinician

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

The major types of crystals containing calcium, which causes arthropathy and periarticular disease, are calcium pyrophosphate dihydrate and basic calcium phosphates, including hydroxyapatite. Exciting advances include the identification of mutations in the gene ANKH associated with disordered inorganic pyrophosphate (PPi) transport in some kindred with familial chondrocalcinosis linked to chromosome 5p. In addition, central basic mechanisms governing cartilage calcification and their relationship to aging and osteoarthritis have now been elucidated. These include the role of plasma cell glycoprotein-1, the PPi-generating ecto-enzyme, in chondrocalcinosis and the linkage of low-grade inflammation to expression and activation of two cartilage-expressed transglutaminase isoenzymes with direct calcification-stimulating activity. This review discusses clinically pertinent new information on pathogenesis. The authors also address, in detail, current diagnostic and therapeutic issues pertaining to calcium pyrophosphate dihydrate and hydroxyapatite crystal deposition in the joint, as well as possible therapeutic directions for the future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Terkeltaub RA: What does cartilage calcification tell us about osteoarthritis? J Rheumatol 2002, 29:411–415.

    PubMed  Google Scholar 

  2. Jaovisidha K, Rosenthal AK: Calcium crystals in osteoarthritis. Curr Opin Rheumatol 2002, 14:298–302.

    Article  PubMed  CAS  Google Scholar 

  3. Johnson K, Hashimoto S, Lotz M, et al.: Up-regulated expression of the phosphodiesterase nucleotide pyrophosphatase family member PC-1 is a marker and pathogenic factor for knee meniscal cartilage matrix calcification. Arthritis Rheum 2001, 44:1071–1081. Using immunohistochemistry and transfection studies with the three different NTPPPH isoenzymes, the authors identify PC-1 as a direct pathogenic factor for cartilage matrix calcification.

    Article  PubMed  CAS  Google Scholar 

  4. Johnson K, Vaingankar S, Chen Y, et al.: Differential mechanisms of inorganic pyrophosphate production by plasma cell membrane glycoprotein-1 and B10 in chondrocytes. Arthritis Rheum 1999, 42:1986–1997. The authors demonstrated the mechanism for TGFβ-induced extracellular PPi elevation to involve PC-1 expression and translocation to the plasma membrane.

    Article  PubMed  CAS  Google Scholar 

  5. Terkeltaub R: Inorganic pyrophosphate generation and disposition in pathophysiology. AJP Cell Physiol 2001, 281:C1-C11. This comprehensive review summarizes recent developments in the understanding of the generation and disposal of PPi and discusses the role of PPi metabolism in diseases with connective tissue calcification.

    CAS  Google Scholar 

  6. Rosenthal AK, Cheung HS, Ryan LM: Transforming growth factor- beta-1 stimulates inorganic pyrophosphate elaboration by porcine cartilage. Arthritis Rheum 1991, 34:904–911.

    Article  PubMed  CAS  Google Scholar 

  7. Rutsch F, Vaingankar S, Johnson K, et al.: PC-1 nucleoside triphosphate pyrophosphohydrolase deficiency in idiopathic infantile arterial calcification. Am J Pathol 2001, 158:543–554. Marked PC-1/NTPPPH deficiency and extracellular PPi deficiency were identified in a male infant with idiopathic infantile arterial and periarticular calcifications with HA crystals. The phenotype was similar in many respects to that of PC-1-deficient mice.

    PubMed  CAS  Google Scholar 

  8. Masuda I, Hamada J, Haas AL, et al.: A unique ectonucleotide pyrophosphohydrolase associated with porcine chondrocytederived vesicles. J Clin Invest 1995, 95:699–704.

    Article  PubMed  CAS  Google Scholar 

  9. Lotz M, Rosen F, McCabe G, et al.: Interleukin 1 beta suppresses transforming growth factor-induced inorganic pyrophosphate [PPi] production and expression of the PPigenerating enzyme PC-1 in human chondrocytes. Proc Natl Acad Sci U S A 1995, 92:10364–10368.

    Article  PubMed  CAS  Google Scholar 

  10. Rosen F, McCabe G, Quach J, et al.: Differential effects of aging on human chondrocyte responses to transforming growth factor beta: increased pyrophosphate production and decreased cell proliferation. Arthritis Rheum 1997, 40:1275–1281.

    PubMed  CAS  Google Scholar 

  11. Johnson K, Hashimoto S, Lotz M, et al.: IL-1 induces pro-mineralizing activity of cartilage tissue transglutaminase and factor XIIIa. Am J Pathol 2001, 159:149–163. This study links stimulation of articular inflammation to a pro-mineralizing pathway whose activation increases with aging in cartilage.

    PubMed  CAS  Google Scholar 

  12. Ryan LM, Kurup IV, Cheung HS: Transduction mechanisms of porcine chondrocyte inorganic pyrophosphate elaboration. Arthritis Rheum 1999, 42:555–560.

    Article  PubMed  CAS  Google Scholar 

  13. Johnson KA, Hessle L, Vaingankar S, et al.: Osteoblast tissue-nonspecific alkaline phosphatase antagonizes and regulates PC-1. Am J Physiol Regul Integr Comp Physiol 2000, 279:R1365-R1377.

    PubMed  CAS  Google Scholar 

  14. Hessle L, Johnson KA, Anderson HC, et al.: Tissue-nonspecific alkaline phosphatase and plasma cell membrane glycoprotein- 1 are central antagonistic regulators of bone mineralization. Proc Natl Acad Sci U S A 2002, 99:9445–9449. This study demonstrated that PC-1 and TNAP are natural antagonists of calcification via opposing effects on PPi.

    Article  PubMed  CAS  Google Scholar 

  15. Kirsch T, Swoboda B, Nah H: Activation of annexin II and V expression, terminal differentiation, mineralization and apoptosis in human osteoarthritic cartilage. Osteoarthritis Cartilage 2000, 8:294–302.

    Article  PubMed  CAS  Google Scholar 

  16. Rosenthal AK, Henry LA: Thyroid hormones induce features of the hypertrophic phenotype and stimulate correlates of CPPD crystal formation in articular chondrocytes. J Rheumatol 1999, 26:395–401.

    PubMed  CAS  Google Scholar 

  17. Kirsch T, Nah HD, Shapiro IM, Pacifici M: Regulated production of mineralization competent matrix vesicles in hypertrophic chondrocytes. J Cell Biol 1997, 137:1149–1160.

    Article  PubMed  CAS  Google Scholar 

  18. Terkeltaub R, Lotz M, Johnson K, et al.: Parathyroid hormone- related protein (PTHrP) expression is abundant in osteoarthritic cartilage, and the PTHrP 1-173 isoform is selectively induced by TGFβ in articular chondrocytes, and suppresses extracellular inorganic pyrophosphate generation. Arthritis Rheum 1998, 41:2152–2164.

    Article  PubMed  CAS  Google Scholar 

  19. Goomer R, Johnson K, Burton D, et al.: A tetrabasic C-terminal motif determines intracrine regulatory effects of PTHrP 1- 173 on PPi metabolism and collagen synthesis in chondrocytes. Endocrinol 2000, 141:4613–4622.

    Article  CAS  Google Scholar 

  20. Lotz M: The role of nitric oxide in articular cartilage damage. Rheum Dis Clin North Am 1999, 25:269–282.

    Article  PubMed  CAS  Google Scholar 

  21. Cheung HS, Ryan LM: Phosphocitrate blocks nitric oxideinduced calcification of cartilage and chondrocyte-derived apoptotic bodies. Osteoarthritis Cartilage 1999, 7:409–412. In this study, the authors demonstrated that NO-induced calcification of cartilage and cartilage-derived apoptotic bodies were inhibited by phosphocitrate.

    Article  PubMed  CAS  Google Scholar 

  22. Johnson K, Pritzker K, Goding J, et al.: The nucleoside triphosphate pyrophosphohydrolase [NTPPPH] isozyme PC-1 directly promotes cartilage calcification through chondrocyte apoptosis and increased calcium precipitation by mineralizing vesicles. J Rheumatol 2001, 28:2681–2691.

    PubMed  CAS  Google Scholar 

  23. Rosenthal AK, Gohr CM, Henry LA, et al.: Participation of transglutaminase in the activation of latent transforming growth factor-beta-1 in aging articular cartilage. Arthritis Rheum 2000, 43:1729–1733.

    Article  PubMed  CAS  Google Scholar 

  24. Rosenthal AK, Masuda I, Gohr CM, et al.: The transglutaminase, factor XIIIA, is present in articular chondrocytes. Osteoarthritis Cartilage 2001, 9:578–581.

    Article  PubMed  CAS  Google Scholar 

  25. Rosenthal AK, Ryan LM: Aging increases growth factorinduced inorganic pyrophosphate elaboration by articular cartilage. Mech Ageing Dev 1994, 75:35–44.

    Article  PubMed  CAS  Google Scholar 

  26. Rosenthal AK, Derfus BA, Henry LA: Transglutaminase activity in aging articular chondrocytes and articular cartilage vesicles. Arthritis Rheum 1997, 40:966–970.

    Article  PubMed  CAS  Google Scholar 

  27. Ho A, Johnson M, Kingsley DM: Role of the mouse ank gene in tissue calcification and arthritis. Science 2000, 289:265–270. In this groundbreaking work, it was demonstrated that the multipass transmembrane protein (ank) was encoded by the gene mutated in the hyperostotic murine progressive ankylosis ank/ank mice; ank was identified to regulate intracellular to extracellular transport of PPi.

    Article  PubMed  CAS  Google Scholar 

  28. Okawa A, Nakamura I, Goto S, et al.: Mutation in Npps in a mouse model of ossification of the posterior longitudinal ligament of the spine. Nat Genet 1998, 19:271–273.

    Article  PubMed  CAS  Google Scholar 

  29. Nurnberg P, Thiele H, Chandler D, et al.: Heterozygous mutations in ANKH, the human orthology of the mouse progressive ankylosis gene, result in craniometaphyseal dysplasia. Nat Genet 2001, 28:37–41.

    Article  PubMed  CAS  Google Scholar 

  30. Reichenberger E, Tiziani V, Watanabe S, et al.: Autosomal dominant craniometaphyseal dysplasia is caused by mutations in the transmembrane protein ank. Am J Hum Genet 2001, 68:1321–1326.

    Article  PubMed  CAS  Google Scholar 

  31. Hughes AE, McGibbon D, Woodwar E, et al.: Localization of a gene for chondrocalcinosis to chromosome 5p. Hum Mol Genet 1995, 4:1225–1228.

    Article  PubMed  CAS  Google Scholar 

  32. Andrew LJ, Brancolini V, Serrano de la Pena L, et al.: Refinement of the chromosome 5p locus for familial calcium pyrophosphate dihydrate deposition disease. Am J Human Genet 1999, 64:136–145.

    Article  CAS  Google Scholar 

  33. Rojas K, Serrano de la Pena L, Gallardo T, et al.: Physical map and characterization of transcripts in the candidate interval for familial chondrocalcinosis at chromosome 5p15.1 Genomics 1999, 62:177–183.

    Article  CAS  Google Scholar 

  34. Reginato AJ, McCarty DJ, Serrano de la Pena L, et al.: Linkage of a North American kindred with primary calcium pyrophosphate deposition disease [CPPDD] linked to chromosome 5p. Arthritis Rheum 1999, 42:S159.

    Google Scholar 

  35. Pendleton A, Johnson MD, Hughes A, et al.: Mutations in ANKH cause chondrocalcinosis. Am J Hum Genet 2002, 71:933–940. In this landmark study, the authors reported linkage of mutations near the N-terminal of the ANKH gene in certain kindred with familial chondrocalcinosis. A C-terminal mutation of ANKH segregated with sporadic chondrocalcinosis in one subject of 95 tested. Preliminary results in this work suggested the possibility that at least one of these mutations may cause pathologic calcification by augmenting PPi channeling activity ("leaky PPi channel").

    Article  PubMed  Google Scholar 

  36. Williams JC, Zhang Y, Timms A, et al.: Autosomal dominant familial calcium pyrophosphate dihydrate deposition disease is caused by mutation in the transmembrane protein ANKH. Am J Hum Genet 2002, 71:985–991. In this landmark study, the authors reported linkage of the P5L mutation in ANKH to autosomal dominant chondrocalcinosis in an Argentine family of northern Italian descent.

    Article  PubMed  Google Scholar 

  37. Lust G, Faure G, Netter P, et al.: Evidence of a generalized metabolic defect in patients with hereditary chondrocalcinosis. Increased inorganic pyrophosphate in cultured fibroblasts and lymphoblasts. Arthritis Rheum 1981, 24:1517–1521.

    Article  PubMed  CAS  Google Scholar 

  38. Lust G, Faure G, Netter P, Seegmiller JE: Increased pyrophosphate in fibroblasts and lymphoblasts from patients with hereditary diffuse articular chondrocalcinosis. Science 1981, 214:809–810.

    Article  PubMed  CAS  Google Scholar 

  39. Maldonado I, Reginato AM, Reginato AJ: Familial calcium crystal disease: what have we learned? Curr Opin Rheumatol 2001, 13:225–233.

    Article  PubMed  CAS  Google Scholar 

  40. Baldwin CT, Farrer LA, Adair R, et al.: Linkage of early-onset osteoarthritis and chondrocalcinosis to human chromosome 8q. Am J Hum Genet 1995, 56:692–697.

    PubMed  CAS  Google Scholar 

  41. Song JS, Lee YH, Kim SS, et al.: A case of calcium pyrophosphate dihydrate crystal deposition disease presenting as an acute polyarthritis. J Korean Med Sci 2002, 17:423–425.

    PubMed  Google Scholar 

  42. Doherty M, Dieppe P, Watt I: Pyrophosphate arthropathy: a prospective study. Br J Rheumatol 1993, 32:189–196.

    Article  PubMed  CAS  Google Scholar 

  43. Reuge L, Lindhoudt DV, Geerster J: Local deposition of calcium pyrophosphate crystals in evolution of knee osteoarthritis. Clin Rheumatol 2001, 20:428–431. The authors observed patients with knee OA with or without detectable CPPD crystals for more than 1 year, and observed that the patients with CPPD crystals needed surgery more compared with those without CPPD crystals.

    Article  PubMed  CAS  Google Scholar 

  44. Derfus BA, Kurian JB, Butler JJ, et al.: The high prevalence of pathologic calcium crystals in pre-operative knees. J Rheumatol 2002, 29:570–574. In this study, CPPD or BCP crystals were detected in the synovial fluid of 60% of patients undergoing total knee arthroplasty. The authors also reported that there were higher mean radiographic scores in correlation with the presence of calcium-containing crystals.

    PubMed  Google Scholar 

  45. Canhao H, Fonseca JE, Leandro MJ, et al.: Cross-sectional study of 50 patients with calcium pyrophosphate dihydrate crystal arthropathy. Clin Rheumathol 2001, 20:119–122. Calcium pyrophosphate dihydrate crystals may affect periarticular sites more often than generally appreciated, as discussed in this study.

    Article  CAS  Google Scholar 

  46. el Maghraoui A, Lecoules S, Lechavalier D, et al.: Acute sacroiliitis as a manifestation of calcium pyrophosphate dihydrate crystal deposition disease. Clin Exp Rheumathol 1999, 17:477–478.

    Google Scholar 

  47. Fujishiro T, Nabeshima Y, Yasui S, et al.: Pseudogout attack of the lumbar facet joint: a case report. Spine 2002, 27:396–398.

    Article  Google Scholar 

  48. Yamakawa K, Iwasaki H, Ohjimi Y, et al.: Tumoral calcium pyrophosphate dihydrate crystal deposition disease. Pathology 2001, 197:499–506. This recent report discloses the importance of clinical manifestations of tumoral CPPD crystal deposits in different anatomic locations, paying particular attention to neurologic findings.

    CAS  Google Scholar 

  49. Pascal-Moussellard H, Cabre P, Smadja D, et al.: Myelopathy due to calcification of the cervical ligamenta flava: a report of two cases in the West Indian patients. Euro Spine J 1999, 8:238–240.

    Article  CAS  Google Scholar 

  50. Cabre P, Pascal-Moussellard H, Kaidomar S, et al.: Six cases of ligamentum cervical flavum calcification in blacks in the French West Indies. Joint Bone Spine 2001, 68:158–165.

    Article  PubMed  CAS  Google Scholar 

  51. Assaker R, Louis E, Boutry N, et al.: Foramen magnum syndrome secondary to calcium pyrophosphate crystal deposition in the transverse ligament of atlas. Spine 2001, 26:1396–1400.

    Article  PubMed  CAS  Google Scholar 

  52. Kakitsubata Y, Boutin RD, Theodorou DJ, et al.: Calcium pyrophosphate dihydrate crystal deposition in and around the atlantoaxial joints: association with type 2 odontoid fractures in nine patients. Radiology 2000, 216:213–219. This is an important report of CPPD deposition in the atlantoaxial joint and methodologic approaches to detect calcifications in this area.

    PubMed  CAS  Google Scholar 

  53. Fisseler-Eckhoff A, Muller KM: Arthroscopy and chondrocalcinosis. Arthroscopy 1992, 8:98–104.

    Article  PubMed  CAS  Google Scholar 

  54. Steinbach LS, Resnick D: Calcium pyrophosphate dihydrate crystal deposition disease: imaging perspective. Curr Probl Diagn Radiol 2000, 29:209–229. This valuable recent review includes detailed information on the radiographic features of CPPD deposition disease.

    Article  PubMed  CAS  Google Scholar 

  55. Sofka CM, Adler RS, Cordasko FA: Ultrasound diagnosis of chondrocalcinosis in the knee. Skeletal Radiol 2002, 31:43–45.

    Article  PubMed  Google Scholar 

  56. Foldes K: Knee chondrocalcinosis an ultrasonographic study of the hyaline cartilage. J Clin Imaging 2002, 26:194–196.

    Article  Google Scholar 

  57. Galvez J, Saiz E, Linares LF, et al.: Delayed examination of synovial fluid by ordinary and polarized light microscopy to detect and identify crystals. Ann Rheum Dis 2002, 61:444–447. oThe authors evaluated the effects of time and preservative on findings in examination for crystals in synovial fluid.

    Article  PubMed  CAS  Google Scholar 

  58. Petrocelli A, Wong AL, Sweezy RL: Identification of pathologic synovial fluid crystals on Gram stains. J Clin Rheumathol 1998, 4:103–105.

    Google Scholar 

  59. Selvi E, Manganelli S, Catenaccio M, et al.: Diff Quik staining method for detection and identification of monosodium urate and calcium pyrophosphate crystals in synovial fluids. Ann Rheum Dis 2001, 60:194–198.

    Article  PubMed  CAS  Google Scholar 

  60. Ohira T, Ishikawa K: Preservation of calcium pyrophosphate dihydrate crystals: effect of Mayer’s hematoxylin staining period. Ann Rheum Dis 2001, 60:80–82.

    Article  PubMed  CAS  Google Scholar 

  61. Roane DW, Harris MD, Carpenter MT, et al.: Prospective use of intramuscular triamcinolone acetonide in pseudogout. J Rheumatol 1997, 24:1168–1170.

    PubMed  CAS  Google Scholar 

  62. Robertson CR, Rice CR, Allen NB: Treatment of erosive osteoarthritis with hydroxychloroquine [abstract]. Arthritis Rheum 1993, 36(suppl):S167.

    Google Scholar 

  63. Bryant LR, des Rosier KF, Carpenter MT: Hydroxychloroquine in the treatment of erosive osteoarthritis. J Rheumatol 1995, 22:1527–1531.

    PubMed  CAS  Google Scholar 

  64. Punzi L, Bertazzolo N, Pianon M, et al.: Soluble interleukin 2 receptors and treatment with hydroxychloroquine in erosive osteoarthritis. J Rheumatol 1996, 23:1477–1778.

    PubMed  CAS  Google Scholar 

  65. Rothschild B, Yakubov LE: Prospective 6-month, double-blind trial of hydroxychloroquine treatment of CPPD. Compr Ther 1997, 23:327–331.

    PubMed  CAS  Google Scholar 

  66. Das SK, Mishra K, Ramakrishnan S, et al.: A randomized controlled trial to evaluate the slow-acting symptom modifying effects of a regimen containing colchicine in a subset of patients with osteoarthritis of the knee. Osteoarthritis Cartilage 2002, 10:247–252.

    Article  PubMed  CAS  Google Scholar 

  67. Das SK, Ramakrishnan S, Mishra K, et al.: A randomized controlled trial to evaluate the slow-acting symptom modifying effects of colchicine in osteoarthritis of the knee: a preliminary report. Arthritis Care Res 2002, 47:280–284.

    Article  CAS  Google Scholar 

  68. Smilde TJ, Haverman JF, Schipper P, et al.: Familial hypokalemia/ hypomagnesemia and chondrocalcinosis. J Rheumatol 1994, 21:1515–1519.

    PubMed  CAS  Google Scholar 

  69. Rosenthal AK, Ryan LM: Treatment of refractory crystal-associated arthritis. Rheum Dis Clin North Am 1995, 21:151–161.

    PubMed  CAS  Google Scholar 

  70. Rosenthal AK, Ryan LM: Probenecid inhibits transforming growth factor-beta 1 induced pyrophosphate elaboration by chondrocytes. J Rheumatol 1994, 21:896–900.

    PubMed  CAS  Google Scholar 

  71. Cini R, Chindamo D, Catenaccio M, et al.: Dissolution of calcium pyrophosphate crystals by polyphosphates: an in vitro and ex vivo study. Ann Rheum Dis 2001, 60:962–967.

    Article  PubMed  CAS  Google Scholar 

  72. Sarkozi AM, Nemeth-Csoka M, Bartosiewicz G: Effects of glycosaminoglican polysulphate in the treatment of chondrocalcinosis. Clin Exp Rheumatol 1988, 6:38.

    Google Scholar 

  73. Disla E, Infante R, Fahmy A, et al.: Recurrent acute calcium pyrophosphate dihydrate arthritis following intra-articular hyaluronate injection. Arthritis Rheum 1999, 42:1302–1303.

    Article  PubMed  CAS  Google Scholar 

  74. Bernardeau C, Bucki B, Liote F: Acute arthritis after intra-articular hyaluronate injection: onset of effusions without crystals. Ann Rheum Dis 2000, 60:518–520.

    Article  Google Scholar 

  75. Kroesen S, Schmid W, Theiler R: Induction of an acute attack of calcium pyrophosphate dihydrate arthritis by intra-articular injection of hylan G-F 20. Clin Rheumatol 2000, 19:147–149.

    Article  PubMed  CAS  Google Scholar 

  76. Kalunian KC, Ike RW, Seeger LL, et al.: Visually guided irrigation in patients with early knee osteoarthritis: a multicenter randomized, controlled trial. Osteoarthritis Cartilage 2000, 8:412–418.

    Article  PubMed  CAS  Google Scholar 

  77. Hashimoto S, Ochs RL, Rosen F, et al.: Chondrocyte-derived apoptotic bodies and calcification of articular cartilage. Proc Natl Acad Sci U S A 1998, 95:3094–3099.

    Article  PubMed  CAS  Google Scholar 

  78. McCarthy GM, Westfall PR, Masuda I, et al.: Basic calcium phosphate crystals activate human osteoarthritic synovial fibroblast and induce matrix metalloproteinases-13 (collagenase- 3) in adult porcine articular condrocytes. Ann Rheum Dis 2001, 60:399–406.

    Article  PubMed  CAS  Google Scholar 

  79. Bai G, Howell DS, Howard GA, et al.: Basic calcium phosphate crystals up-regulate metalloproteinases but down-regulate tissue inhibitor of metalloproteinases-1 and -2 in human fibroblasts. Osteoarthritis Cartilage 2001, 9:416–422.

    Article  PubMed  CAS  Google Scholar 

  80. Reuben PM, Brogley MA, Sun Y, et al.: Molecular mechanism of the induction of metalloproteinases 1 and 3 in human fibroblast by basic calcium phosphate crystals. J Biol Chem 2002, 277:15190–15198.

    PubMed  CAS  Google Scholar 

  81. Morgan MP, McCarthy GM: Signaling mechanisms involved in crystal-induced tissue damage. Curr Opin Rheumatol 2002, 14:292–297.

    Article  PubMed  CAS  Google Scholar 

  82. Pons-Estel BA, Gimenez C, Sacnun M, et al.: Familial osteoarthritis and Milwaukee shoulder associated with calcium pyrophosphate and apatite crystal deposition. J Rheumatol 2000, 27:471–480.

    PubMed  CAS  Google Scholar 

  83. Farin PU, Jaroma H, Soimakallio S: Rotator cuff calcifications: treatment with US-guided technique. Radiology 1995, 195:841–843.

    PubMed  CAS  Google Scholar 

  84. Farin PU, Rasenen H, Jaroma H, et al.: Rotator cuff calcifications: treatment with ultrasound-guided percutaneous needle aspiration and lavage. Skeletal Radiol 1996, 25:551–554.

    Article  PubMed  CAS  Google Scholar 

  85. Aina R, Cardinal E, Bureau NJ, et al.: Calcific shoulder tendonitis: treatment with modified US-guided fine-needle technique. Radiology 2001, 221:455–461.

    Article  PubMed  CAS  Google Scholar 

  86. Gorkiewicz R: Ultrasound therapy of subacromial bursitis: a case report. Phys Ther 1984, 64:46–47.

    PubMed  CAS  Google Scholar 

  87. Crevenna R, Keilani M, Wiesinger G, et al.: Calcific trochanteric bursitis: resolution of calcifications and clinical remission with non-invasive treatment: a case report. Wien Klin Wochenschr 2002, 114:345–348.

    PubMed  Google Scholar 

  88. Downing DS, Weinstein A: Ultrasound therapy of subacromial bursitis: a double blind trial. Phys Ther 1986, 66:194–199.

    PubMed  CAS  Google Scholar 

  89. Ebenbicher G, Erdogmus C, Resch K, et al.: Ultrasound therapy for calcific tendonitis of the shoulder. N Engl J Med 1999, 340:1533–1538.

    Article  Google Scholar 

  90. Chiou HJ, Chou YH, Wu YH, et al.: The role of high-resolution ultrasonography in management of calcific tendonitis of the rotator cuff. Ultrasound Med Biol 2001, 27:735–743.

    Article  PubMed  CAS  Google Scholar 

  91. Cheung HS: Phosphocitrate as a potential therapeutic strategy for crystal deposition disease. Curr Rheumatol Rep 2001, 3:24–28. This is an important review of phosphocitrate and its potential applications in calcific crystal deposition diseases.

    PubMed  CAS  Google Scholar 

  92. Krug HE, Mahowald ML, Halverson PB, et al.: Phosphocitrate prevents disease progression in murine progressive ankylosis. Arthritis Rheum 1993, 36:1603–1611.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Section of Rheumatology, Gulhane Military Medical School, Etlik Ankara, Turkey

    Salih Pay MD

Authors
  1. Salih Pay MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert Terkeltaub MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pay, S., Terkeltaub, R. Calcium pyrophosphate dihydrate and hydroxyapatite crystal deposition in the joint: New developments relevant to the clinician. Curr Rheumatol Rep 5, 235–243 (2003). https://doi.org/10.1007/s11926-003-0073-x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-003-0073-x

Keywords

Search

Navigation